How does maximizing shareholder value distort drug development?
Jul 28, 2016•18 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
With the emergence of sofobuvir, a new direct acting antiviral, treatment for Hepatitis C infection is currently undergoing it's greatest change since the discovery of the virus 25 years ago.
However Gilead, who manufacture the treatment, are under fire for the cost of the druge - around $90 000 for a course of treatment.
Victor Roy, doctoral researcher at the University of Cambridge, discusses how the new drug was discovered and came to market, and what happened to the profits from sale.
Read the full analysis:
For the best experience, listen in Metacast app for iOS or Android